Actively Recruiting
Phase III Double-Blind Study Comparing Monthly Subcutaneous Ianalumab to Placebo in Adults With High Symptom Burden Sjgrens Disease
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
570
Participants Needed
33
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a drug called ianalumab VAY736 given as a monthly injection under the skin for one year. This study focuses on adults with Sjgrens disease who experience a high level of symptoms. The trial is a Phase III, double-blind, randomized study comparing ianalumab to a placebo to assess how well it reduces symptoms and improves quality of life. Participants will receive either 300 mg of ianalumab or a placebo once a month by subcutaneous injection for 52 weeks. The study has two groups one receiving the active drug and the other receiving placebo injections. The aim is to see how ianalumab affects dryness symptoms and other disease-related measures compared to placebo during the treatment period. During the study, participants will be closely monitored with various assessments including symptom scores, saliva flow tests, and quality of life questionnaires over the 52 weeks. Researchers will track changes in oral dryness and other symptoms, fatigue, and overall well-being. Safety and side effects will be monitored throughout the treatment period, and participants will have regular visits for evaluations.
CONDITIONS
Brief Title
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here